Bio-company Organoid Science (CEO Jong-Man Yoo) received the Prime Minister's Award at the '60th Invention Day' ceremony held on the 19th.
This award is hosted by the Ministry of Trade, Industry and Energy and the Korean Intellectual Property Office and organized by the Korea Invention Promotion Association, and is presented annually to companies and individuals who have contributed to technological innovation and intellectual property creation.
Organoid Science is a leading domestic company that has developed and commercialized 'organoids' with structures and functions similar to human organs. Organoids are mini-organs created by culturing cells in a laboratory, and are attracting attention as a future technology that can replace existing animal testing.
Organoid Science received this award in recognition of its ability to secure a number of key patents based on organoid platform technology and to apply them to actual industries, thereby enhancing the technological competitiveness of the domestic bio ecosystem.
In particular, Organoid Science is providing non-clinical trials using mini-organs similar to human organs in cooperation with domestic and foreign pharmaceutical companies, and is receiving attention for its technology that provides data closer to actual human reactions while reducing time and cost.
Organoid Science CTO and Managing Director Kyung-Jin Lee said in his acceptance speech, “This technology is not something that simply ends in the lab, but a platform that can actually change people’s lives.” He added, “We will continue to contribute to human health through creative technology development and intellectual property protection.”
The global bio industry is now rapidly shifting toward a new paradigm called 'animal-free testing'. The U.S. Food and Drug Administration (FDA) has passed a law that will no longer require animal testing for new drug reviews by 2023, and the European Union (EU), Japan, and others are also pursuing similar deregulation. The technology at the center of this is 'organoid'.
In line with this trend, Organoid Science is rapidly growing by concluding numerous contracts with domestic and foreign bio companies by advancing animal alternative testing methods and new drug screening platforms using organoids.
In addition, Organoid Science was recognized for both its technological prowess and business viability in 2023 when its organoid regenerative therapy production technology was designated as a ‘national cutting-edge strategic technology’ and in 2024, it was listed on KOSDAQ based on the technology.
Organoid Science is creating new standards for the bio industry by proactively pursuing technological innovation and global regulatory responses based on the vision of ‘realizing human health through new science.’
Yoo Jong-man, CEO of Organoid Science, said, “The organoids we create are not simply tools for biological experiments, but are a key to changing the future of life sciences.” He added, “We will continue to develop technologies that can provide a better life for both humans and animals.”
- See more related articles
You must be logged in to post a comment.